

AMENDMENT TO RULES COMMITTEE PRINT 116–

57

OFFERED BY MR. WENSTRUP OF OHIO

At the end of subtitle D of title VII, add the following new section:

1 SEC. 7 ____ . STUDY ON JOINT DEPLOYMENT FORMULARY.

2 (a) STUDY.—Not later than 270 days after the date
3 of the enactment of this Act, the Secretary of Defense,
4 in consultation with the Secretary of Health and Human
5 Services, the Commissioner of Food and Drugs, and the
6 heads of other departments and agencies of the Federal
7 Government that the Secretary of Defense determines ap-
8 propriate, shall submit to the appropriate congressional
9 committees a report containing a study on the joint de-
10 ployment formulary

11 (b) ELEMENTS.—The study under subsection (a)
12 shall include—

13 (1) a list of the drugs and vaccines on the joint
14 deployment formulary;

15 (2) an identification of the active pharma-
16 ceutical ingredients of such drugs and vaccines and
17 the components of such active pharmaceutical ingre-
18 dients;

1 (3) the country of origin of—

2 (A) the active pharmaceutical ingredients;

3 (B) the components of such ingredients;

4 and

5 (C) the source materials of such ingredi-
6 ents and components;

7 (4) a list of each manufacturer of such drugs
8 and vaccines that is owned, in whole or in part, by
9 a foreign entity, including—

10 (A) identification of each such foreign enti-
11 ty; and

12 (B) the percentage of such ownership by
13 each such foreign entity;

14 (5) identification of any barriers, limitations, or
15 constraints that may inhibit the ability of the De-
16 partment of Defense to procure and sustain its sup-
17 ply of drugs and vaccines, including with respect
18 to—

19 (A) the Federal Acquisition Regulation;

20 (B) applicable laws and regulations of the
21 Federal Government; and

22 (C) whether the raw materials can be
23 found in the United States;

1 (6) an identification of military partners and al-
2 lies of the United States who could help manufac-
3 ture such components and materials;

4 (7) an assessment of the steps the Secretary of
5 Defense is currently taking to mitigate any short-
6 ages of critical drugs and vaccines on the joint de-
7 ployment formulary;

8 (8) a description of how the Secretary of De-
9 fense coordinates with the Secretary of Health and
10 Human Services, the Commissioner of Food and
11 Drugs, the Secretary of Commerce, the Secretary of
12 Veterans Affairs, and other applicable heads of de-
13 partments and agencies of the Federal Government;
14 and

15 (9) if the Secretary is unable to provide any of
16 the information under paragraphs (1) through (8),
17 identification of any barriers in providing such infor-
18 mation.

19 (c) FORM.—

20 (1) IN GENERAL.—The report submitted under
21 subsection (a) shall be submitted in classified form
22 and shall include an unclassified summary.

23 (2) PROTECTION OF INFORMATION.—The Sec-
24 retary of Defense—

1 (A) shall ensure that the unclassified sum-
2 mary described in paragraph (1) protects pro-
3 prietary information pursuant to the Federal
4 Acquisition Regulation and the Defense Federal
5 Acquisition Regulation; and

6 (B) may not disclose in such unclassified
7 summary any information that is a trade secret
8 under section 552(b)(4) of title 5, United
9 States Code, or confidential information under
10 section 1905 of title 18, United States Code.

11 (d) APPROPRIATE CONGRESSIONAL COMMITTEES
12 DEFINED.—In this section, the term “appropriate con-
13 gressional committees” means—

14 (1) the congressional defense committees;
15 (2) the Committee on Energy and Commerce of
16 the House of Representatives and the Committee on
17 Health, Education, Labor, and Pensions of the Sen-
18 ate; and

19 (3) any other committee of Congress the Sec-
20 retary of Defense determines appropriate.

